Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of GAHT on Arterial Stiffness in Transgender Subjects (Evinge)
NCT04971447Unknown
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Aug 2022
- Primary completion
- Sep 2023
- Modality
- Peptides, Small Molecules
01
Overview
Open-label trial of testosterone enanthate, DehydraTECH-estrogen and gonadotropin-releasing hormone agonist in gender dysphoria (GD) (4 arms), sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Pulse Wave Velocity at 24 months. Status: unknown.
02
Drugs
testosterone enanthateDehydraTECH-estrogengonadotropin-releasing hormone agonist
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on NCT04971447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971447.